Literature DB >> 27161431

Overall and recurrence-free survival among black and white bladder cancer patients in an equal-access health system.

Jill K Schinkel1, Stephanie Shao2, Shelia H Zahm3, Katherine A McGlynn3, Craig D Shriver4, Kangmin Zhu5.   

Abstract

BACKGROUND: While the incidence of bladder cancer is twice as high among whites than among blacks, mortality is higher among blacks than whites. Unequal access to medical care may be an important factor. Insufficient access to care could delay cancer detection and treatment, which can result in worse survival. The purpose of this study was to evaluate whether survival differed between black and white bladder cancer patients in the Department of Defense (DoD), which provides universal healthcare to all beneficiaries regardless of racial background.
METHODS: This study was based on data from the U.S. DoD Automated Central Tumor Registry (ACTUR). White and black patients histologically diagnosed with bladder cancer between 1990 and 2004 were included in the study and followed to the end of 2007. The outcomes were all-cause mortality and recurrence. We assessed the relationship between race and outcomes of interest using Cox proportional hazard ratios (HRs) for all, non-muscle invasive (NMIBC), and muscle invasive (MIBC) bladder cancers, separately.
RESULTS: The survival of black and white individuals did not differ statistically. No significant racial differences in survival (HR: 0.96, 95% CI: 0.76-1.22) or recurrence-free survival (HR: 0.94, 95% CI: 0.69-1.30) were observed after adjustment for demographic variables, tumor characteristics, and treatment. Similar findings were observed for NMIBC and MIBC patients, respectively.
CONCLUSION: Black patients were more likely to present with MIBC than white patients. However, white and black patients with bladder cancer were not significantly different in overall and recurrence-free survival regardless of muscle invasion. Our study suggests the importance of equal access to healthcare in reducing racial disparities in bladder cancer survival.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bladder cancer; Race; Survival

Mesh:

Year:  2016        PMID: 27161431      PMCID: PMC5727912          DOI: 10.1016/j.canep.2016.04.012

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  27 in total

Review 1.  Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.

Authors:  M Craig Hall; Sam S Chang; Guido Dalbagni; Raj Som Pruthi; John Derek Seigne; Eila Curlee Skinner; J Stuart Wolf; Paul F Schellhammer
Journal:  J Urol       Date:  2007-12       Impact factor: 7.450

2.  Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006.

Authors:  Matthew E Nielsen; Angela B Smith; Anne-Marie Meyer; Tzy-Mey Kuo; Seth Tyree; William Y Kim; Matthew I Milowsky; Raj S Pruthi; Robert C Millikan
Journal:  Cancer       Date:  2013-10-10       Impact factor: 6.860

3.  Colorectal cancer testing in the national Veterans Health Administration.

Authors:  Millie D Long; Trang Lance; Douglas Robertson; Leila Kahwati; Linda Kinsinger; Deborah A Fisher
Journal:  Dig Dis Sci       Date:  2011-09-16       Impact factor: 3.199

4.  Racial disparity in bladder cancer: trends in tumor presentation at diagnosis.

Authors:  Cheryl T Lee; Rodney L Dunn; Candice Williams; Willie Underwood
Journal:  J Urol       Date:  2006-09       Impact factor: 7.450

Review 5.  Gender, racial and age differences in bladder cancer incidence and mortality.

Authors:  Ralph Madeb; Edward M Messing
Journal:  Urol Oncol       Date:  2004 Mar-Apr       Impact factor: 3.498

6.  Association between race and survival of patients with non--small-cell lung cancer in the United States veterans affairs population.

Authors:  Apar Kishor Ganti; Shanmuga P Subbiah; Anne Kessinger; Wilson I Gonsalves; Peter T Silberstein; Fausto R Loberiza
Journal:  Clin Lung Cancer       Date:  2013-11-14       Impact factor: 4.785

7.  Recurrence of high-risk bladder cancer: a population-based analysis.

Authors:  Karim Chamie; Mark S Litwin; Jeffrey C Bassett; Timothy J Daskivich; Julie Lai; Jan M Hanley; Badrinath R Konety; Christopher S Saigal
Journal:  Cancer       Date:  2013-06-04       Impact factor: 6.860

8.  Survival experience of black patients and white patients with bladder carcinoma.

Authors:  George R Prout; Margaret N Wesley; Peter G McCarron; Vivien W Chen; Raymond S Greenberg; Robert M Mayberry; Brenda K Edwards
Journal:  Cancer       Date:  2004-02-01       Impact factor: 6.860

9.  Racial and socioeconomic factors in cancer survival. A comparison of Veterans Administration results with selected studies.

Authors:  W F Page; A J Kuntz
Journal:  Cancer       Date:  1980-03-01       Impact factor: 6.860

10.  EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines.

Authors:  J Alfred Witjes; Eva Compérat; Nigel C Cowan; Maria De Santis; Georgios Gakis; Thierry Lebret; Maria J Ribal; Antoine G Van der Heijden; Amir Sherif
Journal:  Eur Urol       Date:  2013-12-12       Impact factor: 20.096

View more
  8 in total

Review 1.  Bladder Cancer Survivorship.

Authors:  Sumeet K Bhanvadia
Journal:  Curr Urol Rep       Date:  2018-11-09       Impact factor: 3.092

2.  DNA methylation patterns in bladder tumors of African American patients point to distinct alterations in xenobiotic metabolism.

Authors:  Venkatrao Vantaku; Chandra Sekhar Amara; Danthasinghe Waduge Badrajee Piyarathna; Sri Ramya Donepudi; Chandrashekar R Ambati; Vasanta Putluri; Wei Tang; Kimal Rajapakshe; Marcos Roberto Estecio; Martha K Terris; Patricia D Castro; Michael M Ittmann; Stephen B Williams; Seth P Lerner; Arun Sreekumar; Roni Bollag; Cristian Coarfa; Michael D Kornberg; Yair Lotan; Stefan Ambs; Nagireddy Putluri
Journal:  Carcinogenesis       Date:  2019-11-25       Impact factor: 4.944

3.  Association of Health-Care System and Survival in African American and Non-Hispanic White Patients With Bladder Cancer.

Authors:  Nikhil V Kotha; Abhishek Kumar; Edmund M Qiao; Alex S Qian; Rohith S Voora; Vinit Nalawade; A Karim Kader; Rana R McKay; Tyler F Stewart; Brent S Rose
Journal:  J Natl Cancer Inst       Date:  2022-04-11       Impact factor: 13.506

4.  Ribosome Binding Protein 1 Correlates with Prognosis and Cell Proliferation in Bladder Cancer.

Authors:  Shuang-Wu Lv; Zhen-Guo Shi; Xiao-Hui Wang; Peng-Yi Zheng; Hui-Bing Li; Qing-Jiang Han; Zhi-Jun Li
Journal:  Onco Targets Ther       Date:  2020-07-07       Impact factor: 4.147

5.  OUTCOMES OF INTRAVESICAL BACILLUS CALMETTE-GUERIN IN A MULTIRACIAL COHORT WITH NON-MUSCLE-INVASIVE BLADDER CANCER.

Authors:  Emily Barry; Ilir Agalliu; Richard Maiman; Evan Shreck; Evan Kovac; Ahmed Aboumohamed; Alexander Sankin
Journal:  Urol Pract       Date:  2021-01-01

Review 6.  Advances in bladder cancer biology and therapy.

Authors:  Linda Tran; Jin-Fen Xiao; Neeraj Agarwal; Jason E Duex; Dan Theodorescu
Journal:  Nat Rev Cancer       Date:  2020-12-02       Impact factor: 69.800

7.  Epidemiology and Hospitalization Cost of Bladder Cancer in Kerman Province, Southeastern Iran.

Authors:  Hamideh Rashidian; Kazem Zendehdel; Rajabali Daroudi; Mohammad Reza Ebadzadeh; Ali Akbar Haghdoost
Journal:  Iran J Public Health       Date:  2018-04       Impact factor: 1.429

8.  Occupational disparities in bladder cancer survival: A population-based cancer registry study in Japan.

Authors:  Masayoshi Zaitsu; Hye-Eun Lee; Sangchul Lee; Takumi Takeuchi; Yasuki Kobayashi; Ichiro Kawachi
Journal:  Cancer Med       Date:  2019-12-11       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.